Treatment of immune-mediated inflammatory neuropathies

Current Opinion in Neurology

Volumn 12, Issue 5, 1999, Pages 573-579

  Hadden, Robert D M ^a   Hughes, Richard A C ^a  

^a GUY S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; AZATHIOPRINE; BETA1A INTERFERON; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; FUSIDATE SODIUM; IMMUNOGLOBULIN; PREDNISOLONE;

CORTICOSTEROID THERAPY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNE RESPONSE; MOTOR NEUROPATHY; NERVE BLOCK; NERVOUS SYSTEM INFLAMMATION; PLASMAPHERESIS; REVIEW;

ADRENAL CORTEX HORMONES; ANIMALS; GUILLAIN-BARRE SYNDROME; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULINS, INTRAVENOUS; MOTOR NEURON DISEASE; NEURAL CONDUCTION; NEURITIS; PLASMA EXCHANGE; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING;

EID: 0033395975     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199910000-00011     Document Type: Review

References (81)

1. 1 Dunn L, Annane D, Gunn A, et al. Cochrane Neuromuscular Disease Review Group Module. In: The Cochrane Library. Oxford: Update Software. 1998. http://www.cochrane.org/cochrane/cdsr.htm. This Internet site describes the scope of the systematic reviews planned and explains how to access the information or contribute.
2. 2 Gold R, Archelos JJ, Hartung H-P. Mechanisms of immune regulation in the peripheral nervous system. Brain Pathol 1999; 9:343-60. A detailed review is provided of molecular immune mechanisms in initiation and regulation of EAN, mentioning which stages are amenable to therapy.
3. 3 Zhu J, Bai XF, Hedlund G, Bjork J, Bakhiet M, Van der Meide PH, et al. Linomide suppresses experimental autoimmune neuritis in Lewis rats by inhibiting myelin antigen-reactive T and B cell responses. Clin Exp Immunol 1999; 115:56-63. Subcutaneous linomide markedly reduced the severity of EAN, and suppressed antigen-specific T-cell and B-cell responses and proinflammatory cytokines.
4. 4 Karpati T, Karussis D, Abramsky O, Mizrahi-Kill R, Arbell I, Ovadia H. Inhibition of experimental autoimmune neuritis by the immunomodulator linomide. Immunol Lett 1998; 63:141-145. Oral linomide caused apoptosis of lymphocytes, downregulated inflammatory cell adhesion molecules, and prevented clinical and pathological signs of EAN.
5. 5 Enders U, Lobb R, Pepinsky RB, Hartung H-P, Toyka KV, Gold R. The role of the very late antigen-4 and its counterligand vascular cell adhesion molecule-1 in the pathogenesis of experimental autoimmune neuritis of the Lewis rat. Brain 1998; 121:1257-1266.
6. 6 Zhu J, Bengtsson BO, Mix E, Ekerling L, Thorell LH, Olsson T, et al. Clomipramine and imipramine suppress clinical signs and T and B cell response to myelin proteins in experimental autoimmune neuritis in Lewis rats. J Autoimmun 1998; 11:319-327. High dose tricyclic antidepressants have an anti-inflammatory effect that suppresses EAN.
7. 7 Shi FD, Bai XF, Xiao BG, Van der Meide PH, Link H. Nasal administration of multiple antigens suppresses experimental autoimmune myashtenia gravis, encephalomyelitis and neuritis. J Neurol Sci 1998; 155:1-12.
8. 8 Zhou LP, Zhu J, Deng GM, Levi M, Wahren B, Diab A, et al. Treatment with P2 protein peptide 57-81 by nasal route is effective in Lewis rat experimental autoimmune neuritis. J Neuroimmunol 1998; 85:137-145. Nasal P2 peptide mildly suppresses EAN when given after onset of clinical signs, but at higher doses than are needed for prevention.
9. 9 Zhu J, Deng GM, Levi M, Wahren B, Diab A, Van der Meide PH, et al. Prevention of experimental autoimmune neuritis by nasal administration of P2 protein peptide 57-81. J Neuropathol Exp Neurol 1998; 57:291-301.
10. 10 Zou LP, Ma D-H, Levi M, Wahren B, Wei L, Mix E, et al. Antigen-specific immunosuppression: nasal tolerance to PO protein peptides for the prevention and treatment of experimental autoimmune neuritis in Lewis rats. J Neuroimmunol 1999; 94:109-121. Nasal PO peptide suppresses EAN when given before immunization or after onset of clinical signs.
11. 11 Zhu J, Mix E, Link H. Cytokine production and the pathogenesis of experimental autoimmune neuritis and Guillain-Barré syndrome. J Neuroimmunol 1998; 84:40-52.
12. 12 Fujioka T, Jimi T, Hilliard BA, Ventura ES, Rostami A. The expression of cytokine mRNA in the cauda equina of Lewis rats with experimental allergic neuritis. J Neuroimmunol 1998; 84:223-229.
13. 13 Smith KJ, Kapoor R, Felts PA. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol 1999; 9:69-92. A comprehensive review is given of the role of reactive oxygen and nitrogen species in inducing demyelination and axonal degeneration. Inhibition of these mechanisms is not always beneficial, but may eventually give new therapeutic possibilities.
14. 14 Miyamoto K, Oka N, Kawasaki T, Satoi H, Akiguchi I, Kimura J. The effect of cyclooxygenase-2 inhibitor on experimental allergic neuritis. NeuroReport 1998; 9:2331-2334. Cyclo-oxygenase-2 inhibitors reduce prostaglandin synthesis but, unlike cyclo-oxygenase 1 inhibitors such as indomethacin and corticosteroids, do not cause gastric irritation. Nimesulide, a cyclo-oxygenase-2 inhibitor, reduced neurological deficit and axonal degeneration in EAN, even when given after onset. Cyclo-oxygenase-2 expression is induced by proinflammatory cytokines, and was expressed in macrophages phagocytosing myelin in a human nerve biopsy.
15. 15 Zhu J, Deng GM, Diab A, Zwingenberger K, Bakhiet M, Link H. Thalidomide prolongs experimental autoimmune neuritis in Lewis rats. Scand J Immunol 1998; 48:397-402.
16. 16 Kurek JB, Radford AJ, Crump DE, Bower JJ, Feeney SJ, Austin L, et al. LIF (AM424), a promising growth factor for the treatment of ALS. J Neurol Sci 1998; 160:S106-S113.
17. 17 Stangel M, Hartung HP, Marx P, Gold R. Intravenous immunogiobulin treatment of neurological autoimmune diseases [review]. J Neurol Sci 1998; 153:203-214.
18. 18 Wills AJ, Unsworth DJ. A practical approach to the use of intravenous immunoglobulin in neurological disease [review]. Eur Neurol 1998; 39:3-8.
19. 19 Dalakas MC. Mechanism of action of intravenous immunogiobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases [review]. Neurology 1998; 51:S2-S8. An excellent review is given of molecular mechanisms of action of IVlg, as well as helpful practical advice on its clinical usage and adverse effects.
20. 20 Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody-mediated autoimmune diseases. N Engl J Med 1999; 340:227-228. This review proposed a novel hypothesis for a mechanism of action of IVlg based on recent molecular research. It suggests that endogenous pathogenic lgG is degraded when excess lgG is infused, because of saturation of the protective binding molecule FcRn. It gives no evidence that this is the only or even the most important mechanism of action of IVlg.
21. 21 Sharief MK, Ingram DA, Swash M, Thompson EJ. IV immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome. Neurology 1999; 52:1833-1838. This interesting observational study of 40 GBS patients found that TNF-α and interleukin-1β levels were reduced by IVlg but remained high in patients treated with plasma exchange or not treated. Clinical improvement correlated with levels of TNF-α. Levels of the anti-inflammatory cytokines interleukin-10 and soluble TNF receptor were not affected by IVlg. This suggests that one mechanism of action of IVlg is to reduce levels of proinflammatory cytokines.
22. 22 Tekgul H, Kutukculer N, Caglayan S, Tutuncuoglu S. Pro-inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in Guillain-Barré syndrome. Turk J Pediatr 1998; 40:357-363.
23. 23 Kuwabara S, Asahina M, Koga M, Mori M, Yuki N, Hattori T. Two patterns of clinical recovery in Guillain-Barré syndrome with lgG anti-GM1 antibody. Neurology 1998; 51:1656-1660.
24. 24 Visser LH, Van der Meche FGA, van Doom PA, Meulstee J, Jacobs BC, Oomes PG, et al. Guillain-Barré syndrome without sensory loss (acute motor neuropathy); a subgroup with specific clinical, electrodiagnostic and laboratory features. Brain 1995; 118:841-847.
25. 25 Yuki N, Tagawa Y, Hirata K. Minimal number of plasma exchanges needed to reduce immunoglobulin in Guillain-Barré syndrome. Neurology 1998; 51:875-877.
26. 26 Yoshii F, Shinohara Y. Natural killer cells in patients with Guillain-Barré syndrome. J Neurol Sci 1998; 157:175-178.
27. 27 Tagawa Y, Yuki N, Hirata K. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption. J Neurol Sci 1998; 157:90-95. A useful comparison of different clinical methods of antibody removal from plasma.
28. 28 Hughes RAC, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial of prednisolone in acute polyneuropathy. Lancet 1978; 2:750-753.
29. 29 Swick HM, McQuillen MP. The use of steroids in the treatment of idiopathic polyneuritis. Neurology 1976; 26:205-212.
30. 30 Hughes RAC, Van der Meché FGA. In: Corticosteroid treatment for Guillain-Barré syndrome (Cochrane review). The Cochrane Library, Issue 2. Oxford: Update Software. 1999. http://www.cochrane.org/cochrane/revabstr/ab001446.htm. This Cochrane systematic review of six randomized trials confirmed the result of the largest single trial that corticosteroid treatment was not effective in GBS.
31. 31 Ono S, Inoue K, Munakata S, Nagao K, Shimizu N. Muscle pathology in the early stage of Guillain-Barré syndrome. Eur Neurol 1998; 39:141-147.
32. 32 Nicoletti F, Nicoletti A, Giuffrida S, Di Marco R, Meroni P, Bendtzen K, et al. Sodium fusidate in Guillain-Barré syndrome: a case report. J Neurol Neurosurg Psychiatry 1998; 65:266-268. Sodium fusidate (Fucidin), a novel immunosuppressant, was given to one GBS patient (1.5 g/day for 1 week) who subsequently recovered rapidly, with marked reductions in blood levels of proinflammatory cytokines.
33. 33 Créange A, Lerat H, Meyrignac C, Degos JD, Gherardi RK, Cesaro P. Treatment of Guillain-Barré syndrome with interferon-beta [Letter]. Lancet 1998; 352:368-369.
34. 34 Graf WD, Katz JS, Eder DN, Smith AJ, Chun MR. Outcome in severe pediatrie Guillain-Barré syndrome after immunotherapy or supportive care. Neurology 1999; 52:1494-1497.
35. 35 Romano JG, Rotta FT, Potter P, Rosenfeld V, Santibanez R, Rocha B, et al. Relapses in the Guillain-Barré syndrome after treatment with intravenous immune globulin or plasma exchange. Muscle Nerve 1998; 21:1327-1330. This retrospective study of 10 patients who relapsed 1 month to 2 years later found that relapses were surprisingly more frequent in those treated with plasma exchange (28%) than IVlg (8%), and in those with an associated medical condition or with longer time until start of treatment.
36. 36 Visser LH, Van der Méche FGA, Meulstee J, van Doom PA, Dutch Guillain-Barré Study Group. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1998; 64:242-244. This prospective Dutch study found treatment-related clinical fluctuations in 16 out of 172 (9%) patients, which were less likely in patients with predominantly distal weakness, antiganglioside GM1 antibodies or normal sensory amplitudes, but which were not related to treatment.
37. 37 Hughes RAC. Management of acute neuromuscular paralysis. J Roy Coll Phys Lond 1998; 32:254-259.
38. 38 Sater RA, Rostami A. Treatment of Guillain-Barré syndrome with intravenous immunoglobulin [review]. Neurology 1998; 51:S9-S15.
39. 39 Hahn AF. Guillain-Barré syndrome [review]. Lancet 1998; 352:635-641. A useful up-to-date review of GBS is presented.
40. 40 Barohn RJ, Saperstein DS. Guillain-Barré syndrome and chronic inflammatory demyelinating polyneuropathy [review]. Semin Neurol 1998; 18:49-61.
41. 41 The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985; 35:1096-1104.
42. 42 French Cooperative Group on plasma exchange in Guillain-Barré syndrome. Plasma exchange in Guillain-Barré syndrome: one-year follow-up. Ann Neurol 1992; 32:94-97.
43. 43 French Cooperative group in plasma exchange in Guillain-Barré syndrome. Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. Ann Neurol 1987; 22:753-761.
44. 44 The French Cooperative Group on Plasma Exchange in Guillain-Barré Syndrome. Appropriate number of plasma exchanges in Guillain-Barré syndrome. Ann Neurol 1997; 41:298-306.
45. 45 Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Lancet 1997; 349:225-230.
46. 46 Van der Meché FGA, Schmitz PIM, Dutch Guillain-Barré Study Group. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. N Engl J Med 1992; 326:1123-1129.
47. 47 Rees JH, Thompson RD, Smeeton NC, Hughes RAC. Epidemiological study of Guillain-Barré syndrome in south east England. J Neurol Neurosurg Psychiatry 1998; 64:74-77. A useful epidemiological survey of GBS in England showed outcome was better for patients treated in a specialist neurology centre compared with a district hospital.
48. 48 Lunn MPT, Manti H, Choudhary PP, Hughes RAC, Thomas PK. Chronic inflammatory demyelinating polyradiculoneuropathy: a prevalence study in south east England. J Neurol Neurosurg Psychiatry 1999; 66:677-680.
49. 49 Bouchard C, Lacroix C, Plante V, Adams V, Chedru F, Guglielmi JM, et al. Clinicopathologic findings and prognosis of chronic inflammatory demyelinating polyneuropathy. Neurology 1999; 52:498-503. A useful analysis of clinical and pathological prognostic indicators in 100 patients with CIDP.
50. 50 Sakakibara R, Hattori T, Kuwabara S, Yamanishi T, Yasuda. Micturitional disturbance in patients with chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 50:1179-1182.
51. 51 Antoine JC, Mosnier JF, Lapras J, Convers P, Absi L, Laurent B, et al. Chronic inflammatory demyelinating polyneuropathy associated with carcinoma. J Neurol Neurosurg Psychiatry 1996; 60:188-190.
52. 52 Abe K, Sugai F. Chronic inflammatory demyelinating polyneuropathy accompanied by carcinoma [letter]. J Neurol Neurosurg Psychiatry 1998; 65:403-404.
53. 53 Weiss MD, Luciano CA, Semino-Mora C, Dalakas MC, Quarles RH. Molecular mimicry in chronic inflammatory demyelinating polyneuropathy and melanoma. Neurology 1998; 51:1738-1741.
54. 54 Bird SJ, Brown MJ, Shy ME, Scherer SS. Chronic inflammatory demyelinating polyneuropathy associated with malignant melanoma. Neurology 1996; 46:822-824.
55. 55 Kubori T, Mezaki T, Kaji R, Kimura J, Hamaguchi K, Hirayama K, et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy [in Japanese]. No Shinkei Brain Nerve 1999; 51:127-135. This is a helpful randomized comparison of three doses of IVlg in CIDP and MMNCB. More effective than lower doses was 2 g/kg.
56. 56 Hattori N, Ichimura M, Aoki S, Nagamatsu M, Yasuda T, Kumazawa K, et al. Clinicopathological features of chronic inflammatory demyelinating polyradiculoneuropathy in childhood. J Neurol Sci 1998; 154:66-71, Two clinical patterns of childhood CIDP may have different treatment responses.
57. 57 Hanaoka N, Hanyu N, Yanagisawa N. Steroid therapy and plasmapheresis in chronic inflammatory demyelinating polyradiculoneuropathy: a long-term follow-up study [in Japanese]. Rinsho Shinkeigaku Clin Neurol 1998; 38:208-212.
58. 58 Briellmann RS, Nydegger UE, Sturzenegger M, Fierz L, Hess CW, Hauser SP. Long-term treatment of chronic relapsing inflammatory demyelinating polyradiculoneuropathy: combination of corticosteroids, plasma exchange, and intravenous immunoglobulins. Eur Neurol 1998; 39:190-191.
59. 59 Samman I, Wohrle JC, Hennerici M. Rational therapy of Guillain-Barré syndrome [letter]. Lancet 1998; 351:753-754. IVlg was more effective in one patient with CIDP as 1 g/kg monthly than in higher doses less frequently.
60. 60 Kumazawa K, Yuasa N, Mitsuma T, Nagamatsu M, Sobue G. Double filtration plasmapheresis (DFPP) in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) [in Japanese]. Rinsho Shinkeigaku Clin Neural 1998; 38:719-723.
61. 61 Good JL, Chehrenama M, Mayer RF, Koski CL. Pulse cyclophosphamide therapy in chronic inflammatory demyelinating polyneuropathy. Neurology 1998; 51:1735-1738. Cyclophosphamide works surprisingly well in CIDP, although long term toxicity is unclear.
62. 62 Hadden RDM, Sharrack B, Bensa S, Soudain SE, Hughes RAC. Randomized trial of interferon β-1 a in chronic inflammatory demyelinating polyradiculoneuropathy. Neurology 1999; 53:57-61. Interferon-β was no more effective than placebo, although patients had treatment-resistant CIDP with probable advanced axonal degeneration.
63. 63 Marzo ME, Tintore M, Fabregues O, Montalban X, Codina A. Chronic inflammatory demyelinating polyneuropathy during treatment with interferon-alpha [Letter]. J Neurol Neurosurg Psychiatry 1998; 65:604.
64. 64 Gorson KC, Ropper AH, Clark BD, Dew RB, Simovic D, Allam G. Treatment of chronic inflammatory demyelinating polyneuropathy with interferon-alpha 2a. Neurology 1998; 50:84-87.
65. 65 Hahn AF. Treatment of chronic inflammatory demyelinating polyneuropathy with intravenous immunoglobulin [review]. Neurology 1998; 51 :S16-S21. This is an authoritative review from the organizer of many treatment trials in CIDP.
66. 66 Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy: a double-blind, placebo-controlled, cross-over study. Brain 1996; 119:1067-1077.
67. 67 Thompson N, Choudhary P, Hughes R, Quinlivan R. A novel trial design to study the effect of intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol 1996; 243:280-285.
68. 68 Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol 1994; 36:838-845.
69. 69 Dyck PJ, O'Brien PC, Oviatt KF, Dinapoli RP, Daube JR, Bartleson JD, et al. Prednisone improves chronic inflammatory demyelinating polyradiculoneuropathy more than no treatment. Ann Neurol 1982; 11:136-141.
70. 70 Hahn AF, Bolton CF, Pillay N, Chalk C, Benstead T, Bril V, et al. Plasma-exchange therapy in chronic inflammatory demyelinating polyneuropathy: a double-blind, sham-controlled, crossover study. Brain 1996; 119:1055-1066.
71. 71 Barnett MH, Pollard JD, Davies L, McLeod JG. Cyclosporin A in resistant chronic inflammatory demyelinating polyradiculoneuropathy. Muscle Nerve 1998; 21:454-460.
72. 72 Chaudhry V. Multifocal motor neuropathy [Review]. Semin Neurol 1998; 18:73-81.
73. 73 Pestronk A. Multifocal motor neuropathy: diagnosis and treatment [Review]. Neurology 1998; 51:S22-S24.
74. 74 Markson L, Janzen D, Bril V. Response to therapy in demyelinating motor neuropathy. Muscle Nerve 1998; 21:1769-1771. In this series IVlg was less beneficial than is commonly expected.
75. 75 Van den Berg LH, Franssen H, Wokke JH. The long-term effect of intravenous immunoglobulin treatment in multifocal motor neuropathy. Brain 1998; 121:421-428. This is the first description of the long-term effect of IVlg in MMNCB.
76. 76 Carpo M, Cappellari A, Mora G, Pedotti R, Barbieri S, Scarlato G, et al. Deterioration of multifocal motor neuropathy after plasma exchange. Neurology 1998; 50:1480-1482.
77. 77 Martina IS, van Doorn PA, Schmitz PI, Meulstee J, Van der Meche FGA. Chronic motor neuropathies: response to interferon beta-1a after failure of conventional therapies. J Neurol Neurosurg Psychiatry 1999; 66:197-201. Interferon-β is worth testing further in MMNCB.
78. 78 de Jager AE, Hazenberg CA, van der Hoeven JH. Rhesus anti-D immunoglobulin in chronic autoimmune neuropathy. Acta Neurol Scand 1998; 98:64-66.
79. 79 Finsterer J, Schwerer B, Bittner RE, Mamoli B. Cerebrospinal fluid filtration and immunoglobulins in multifocal motor neuropathy. Clin Neuropathol 1999; 18:31-36.
80. 80 Van den Berg LH, Kerkhoff H, Oey PL, Franssen H, Mollee I, Vermeulen M, et al. Treatment of multifocal motor neuropathy with high dose intravenous immunoglobulins: a double blind, placebo controlled study. J Neurol Neurosurg Psychiatry 1995; 59:248-252.
81. 81 Donaghy M, Mills KR, Boniface SJ, Simmons J, Wright I, Gregson N, et al. Pure motor demyelinating neuropathy: deterioration after steroid treatment and improvement with intravenous immunoglobultn. J Neurof Neurosurg Psychiatry 1994; 57:778-783.